26, North St

Boston,

MA,

USA,

ZIP: 02109

Phone: (+1) 617 455 4188

There are currently no therapeutics on the market for inner ear disorders, so biotech companies have been paving the way to displace the cochlear implant and cater for the huge unmet need in hearing and balance disorders. With the first in-person gene therapy clinical trial commencing in early 2022, the field is booming with excitement, not to mention pharma sparking an interest with increasing investment into these pipelines in the race to successfully reverse hearing damage.

The 2nd Inner Ear Disorders Therapeutics Summit will unite drug developers focusing on preventative and regenerative approaches targeting the inner ear to debate:
- The Clinical Applicability of Different Modalities Including Small Molecule, Stem Cell and Gene Therapy
- Accurately Monitoring Hearing Loss Progress and Functional Improvement
- Successfully Identifying New Targets of the Inner Ear
- Optimizing Preclinical Models of Hearing and Balance Disorders
- Combination Strategies for Drugs and Devices 
- The Latest Clinical Updates and Novel Translatable Research of the Inner Ear

Join over 100 drug developers from the likes of Otonomy, Harvard Medical School, Frequency Therapeutics, Astellas, Sensorion, Sound Pharmaceuticals and Decibel Therapeutics at this 4-day disease-agnostic, modality-agnostic event designed specifically for industry-based experts in inner ear disorders to successfully translate their therapeutics into the clinic.

Take advantage of our group discounts, academic rates and earlybird savings - don't miss out register now for the best rate!

URLs:
Tickets: https://go.evvnt.com/1053180-2?pid=1052
Brochure: https://go.evvnt.com/1053180-3?pid=1052

Prices:
Drug Developer Pricing - Conference + Workshop Day and Focus Day: USD 5497.00,
Drug Developer Pricing - Conference + Workshop Day: USD 4698.00,
Drug Developer Pricing - Conference + Focus Day: USD 3698.00,
Drug Developer Pricing - Conference Only: USD 2899.00

Carmine Stengone, Chief Executive Officer, Pipeline Therapeutics, David Lucchino Co-Founder, President and Chief Executive Officer, Frequency Therapeutics, Laurence Reid, Chief Executive Officer, Decibel Therapeutics, Alan Foster, Vice President of Research, Otonomy, Anne GM Schilder, Professor of Otolaryngology, Ear Institute, University College London, Jonathan Kil, Chief Executive Officer, Sound Pharmaceuticals, Denise Goldman Vice President, Global Head of Biosciences and Hearing Drug Solutions, Cochlear Ltd, Marcelo Rivolta, Chief Scientific Officer, Rinri Therapeutics, Meghan Drummond, Associate Director, Auditory Sciences, Regeneron, Jonas Dyhrfjeld-Johnsen, Chief Development Officer, Acousia Therapeutics, Nora Yang, Chief Scientific Officer, Sensorion, Stephen Huhn, Chief Medical Officer and Senior Vice President, Clinical Development, Pipeline Therapeutics, Chieri Hayashi, Medical Director, Astellas, Jeff Anderson, Vice President of Clinical Sciences, Otonomy, Steven Rauch, Professor and Vice Chair for Clinical Research, Department of Otolaryngology, Harvard Medical School, Carl LeBel, Chief Development Officer, Frequency Therapeutics, Catherine Perrodin,Translational Research Manager, RNID, Douglas Hartley, Professor of Otology and Consultant ENT surgeon, School of Medicine, University of Nottingham, Geraldine Honnet, Chief Medical Officer, Sensorion, Rick Cousins, Visiting Academic, UCL Ear Institute, Terri Gaskell, Chief Technology Officer, Rinri Therapeutics, David McAlpine, Academic Director, Professor of Hearing, Language and the Brain, Macquarie University, Gary Housley, Professor and Chair of Physiology, Director, Translational Neuroscience Facility, School of Medical Sciences, UNSW, Jian Zuo Professor, Creighton University and Co-founder, Ting Therapeutics, Colleen Le Prell, Professor of Hearing Science, Chair, Department of Speech, Language, and Hearing, University of Texas at Dallas, Fabrice Piu, Senior Vice President - Research and Pre-clinical Development, Otonomy, Nishchay Mehta, Otologist and Auditory Implant Surgeon, Royal National ENT Hospital, UCLH, Per Gjorstrup, President and Chief Executive Officer, Anida Pharma, Reimar Schlingensiepen Chief Scientific Officer AudioCure, Simon Chandler Chief Executive Officer Rinri Therapeutics, Adam Palermo Vice President, Molecular Platform Decibel Therapeutics, Jeffrey Kysar Professor, Dept of Mechanical Engineering, Fu Foundation School of Engineering and Applied Science Columbia University, Kaukab Rajput Consultant Audiovestibular Physician Great Ormond Street Hospital NHS Trust, Anil Lalwani Professor, Dept Otolaryngology-HNS, Vagelos College of Physicians and Surgeons Columbia University, Brenda Battat Ex Executive Director Hearing Loss Association of America, Joseph Burns Vice President, Discovery Decibel Therapeutics, Jeffrey Borenstein Group Lead Bioengineering Draper, Jonathon Whitton Vice President of Clinical Research Decibel Therapeutics, Mathieu Schue Project Director, Drug Development and Translational Research CILcare, Hans Rommelspacher Chief Scientific Officer and Founder AudioCure Pharma, Will McLean Senior Vice President, Hearing and Translational Research Frequency Therapeutics